The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase.
CRF Health, a global provider of eCOA solutions, announced it has agreements with two top tier pharmaceutical companies to support Phase III trials in ovarian and breast cancer. The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase. The three studies-two in breast cancer and one in ovarian--will encompass 542 sites, 23 countries and almost 2,000 female trial participants, across the U.S, Europe and Asia Pacific.
